AC Immune SA
NASDAQ:ACIU

Watchlist Manager
AC Immune SA Logo
AC Immune SA
NASDAQ:ACIU
Watchlist
Price: 2.07 USD 2.48%
Market Cap: 204.8m USD

EV/EBIT
Enterprise Value to EBIT

-0.5
Current
-1.6
Median
4.5
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-0.5
=
Enterprise Value
29.7m USD
/
EBIT
-51.7m CHF
EBIT Growth EV/EBIT to Growth
CH
AC Immune SA
NASDAQ:ACIU
Average EV/EBIT: 20.3
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 340.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -361 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-0.4
2-Years Forward
EV/EBIT
-0.3
3-Years Forward
EV/EBIT
2.9